I need to find the substantive financial/operational disclosure content in this 10-Q filing. The filing text provided is largely the cover page, forward-looking statements cautionary language, and risk factor summary - boilerplate sections. However, there are some specific figures mentioned (share count of 7,063,982, the $36.2 million potential proceeds, $10.50 warrant exercise price) that constitute substantive disclosure content. Let me assess whether the substantive content exceeds 150 words - yes, it does with the specific financial figures and company details disclosed. Now let me craft the article based solely on what is in the filing.

Xilio Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Shares outstanding: As of November 6, 2026, the company had 7,063,982 shares of common stock outstanding at a par value of $0.0001 per share.
  • Potential warrant proceeds: According to the filing, the company disclosed the potential receipt of up to $36.2 million in additional gross proceeds in the fourth quarter of 2026 if all outstanding Series C common stock warrants are exercised at their current exercise price of $10.50 per warrant.
  • Warrant background: The Series C common stock warrants were issued in connection with the company's June 2025 follow-on offering, according to the filing.
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company under applicable Exchange Act definitions.
  • Key collaborations disclosed: The filing references a collaboration agreement with AbbVie Group Holdings Limited and a license agreement with Gilead Sciences, Inc. as material to the company's business.
  • Operating losses: The company disclosed that it "has incurred significant operating losses since our inception and expects to incur significant losses for the foreseeable future."

Xilio Therapeutics' September 2026 Quarterly Disclosures: Warrants, Collaborations, and Capital Needs

Xilio Therapeutics, Inc. (NASDAQ:XLO), a Delaware-incorporated clinical-stage company headquartered at 828 Winter Street, Suite 300, Waltham, Massachusetts, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing carries Commission File Number 001-40925 and was submitted on November 10, 2026.

Among the specific financial disclosures in the filing, the company noted the potential receipt of "up to $36.2 million in additional gross proceeds in the fourth quarter of 2026 if all outstanding Series C common stock warrants issued in connection with our June 2025 follow-on offering are exercised at their current exercise price of $10.50 per warrant." The filing presents this figure in the context of forward-looking statements, which the company cautions are "subject to known and unknown risks, uncertainties and other important factors" that may cause actual results to differ materially.

The filing also identifies the company's collaboration agreement with AbbVie Group Holdings Limited and its license agreement with Gilead Sciences, Inc. as central to its business strategy, noting expectations around milestones, option-related fees, and other contingent payments under those arrangements. The company disclosed that it "will need to obtain substantial additional capital in the future to finance our operations and complete the development of any current or future product candidates," characterizing its business as "highly dependent on the success of our current product candidates." The filing states that the company has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.

What Was Disclosed

Xilio Therapeutics filed its 10-Q for the quarter ended September 30, 2026, disclosing 7,063,982 shares outstanding as of November 6, 2026, up to $36.2 million in potential Series C warrant proceeds at $10.50 per warrant, and ongoing capital needs tied to its clinical-stage pipeline and collaboration agreements.